ライブ
Endpoints NewsDimension seeks up to $750M for third life sciences fund after string of successEndpoints NewsElevance talks 'practical' AIEndpoints NewsMammalian hair, roof leaks: Novo's Catalent site in Indiana under FDA scrutiny once againFierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2Endpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drugCellPaleogenomes reveal the evolutionary relationship between modern and cave lionsEndpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cutsEndpoints NewsSupreme Court sides with Hikma in 'skinny label' caseFierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, tooEndpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinicBioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2BFierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3
BioWorld 2026年2月27日

CSPC Zhongqi Pharmaceutical Technology discovers EGFR PROTAC degraders

CSPC Zhongqi Pharmaceutical Technology discovers EGFR PROTAC degraders

原文
本文は利用できません。元の情報源をご確認ください。